이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

REC 0/0559 성인 환자의 중등도 및 중증 신경영양성 각막염 치료를 위한 안약

2026년 9월 14일 업데이트: RECORDATI GROUP

성인 환자의 2기(중등도) 및 3기(중증) 신경영양성 각막염 치료를 위한 REC 0/0559 점안액 3회 용량의 효능, 안전성 및 약동학

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This was a Phase 2, international, multicentre, dose-ranging, double-masked, randomised, parallel-group, vehicle-controlled study designed to evaluate 3 different doses of REC 0/0559 vs vehicle in patients with Stage 2 and Stage 3 neurotrophic keratitis (NK).

연구 유형

중재적

등록 (실제)

108

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Cologne, 독일, 50924
        • Uniklinik Koeln
      • Düsseldorf, 독일, 40225
        • Hospital Eye University of Duesseldorf
      • Frankfurt, 독일, 60590
        • Universitaetsklinikum Frankfurt
      • Homburg, 독일
        • Saarland University Medical Center
      • Mainz, 독일, 55131
        • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
    • Bavaria
      • Munich, Bavaria, 독일, 80336
        • Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik
    • Florida
      • Crystal River, Florida, 미국, 34429-8722
        • Nature Coast Clinical Research
      • Gainesville, Florida, 미국, 32605
        • University of Florida
    • Maryland
      • Baltimore, Maryland, 미국, 21201
        • University of Maryland School of Medicine UMSOM
    • Michigan
      • Ann Arbor, Michigan, 미국, 48105
        • University of Michigan - Kellogg Eye Center
    • New York
      • New York, New York, 미국, 10003
        • Mt. Sinai New York Eye and Ear Infirmary
    • North Carolina
      • Winston-Salem, North Carolina, 미국, 27157
        • Wake Forest Baptist Medical Center
    • Tennessee
      • Nashville, Tennessee, 미국, 37215
        • Toyos Clinic
    • Texas
      • Houston, Texas, 미국, 77025
        • Houston Eye Associates HEA - Gramercy Location
    • Wisconsin
      • Madison, Wisconsin, 미국, 53705
        • University of Wisconsin-Madison
      • Barakaldo, 스페인, 48903
        • Hospital de Cruces
      • Barcelona, 스페인
        • Centro de Oftalmologia Barraquer
      • Barcelona, 스페인, 08035
        • Instituto Microcirugia Ocular IMO
      • Madrid, 스페인, 28040
        • Hospital Clinico San Carlos
      • Seville, 스페인
        • Cartuja Vision - Centro de Servicios Oftlamologicos
    • Principality of Asturias
      • Oviedo, Principality of Asturias, 스페인, 33012
        • Instituto Oftalmologico Fernandez-Vega
      • Glasgow, 영국, G75 8RG
        • University Hospital Hairmyres
      • London, 영국
        • Moorfields Eye Hospital NHS Foundation Trust
      • Southampton, 영국, SO16 6YD
        • Southampton General Hospital
    • Mersey
      • Liverpool, Mersey, 영국, L7 8XP
        • Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre
      • Bari, 이탈리아, 70124
        • Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica
      • Bologna, 이탈리아, 40138
        • DIMES Universit di Bologna
      • Florence, 이탈리아, 50134
        • Azienda Ospedaliero-Universitaria Careggi
      • Forlì, 이탈리아
        • Ospedali Privato
      • Genova, 이탈리아, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Messina, 이탈리아
        • Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
      • Milan, 이탈리아, 20157
        • Ospedale Luigi Sacco
      • Roma, 이탈리아, 00133
        • Fondazione PTV - Policlinico Tor Vergata
    • Calabria
      • Germaneto, Calabria, 이탈리아, 88100
        • Università Magna Grecia di Catanzaro
      • Dijon, 프랑스, 21000
        • Dijon University Hospital CHU Dijon
      • Paris, 프랑스
        • Hôpital Fondation Adolphe de Rothschild
      • Paris, 프랑스, 75014
        • CHU Paris Centre - Hôpital Cochin
      • Paris, 프랑스
        • Hôpital Universitaire Necker
      • Budapest, 헝가리
        • Semmelweis University, Dept. of Ophthalmology
      • Pécs, 헝가리
        • University of Pecs - Dpt of Ophthalmology
    • Vas County
      • Szombathely, Vas County, 헝가리, 9700
        • Markusovszky University Teaching Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Have read, understood, and signed the informed consent form (ICF).

  2. Be a male or female aged ≥18 years at the time of ICF signature.

  3. Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.

    for the study eye

  4. Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.

  5. Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.

  6. Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.

Exclusion Criteria:

  1. Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.

  2. Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8

  3. Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.

  4. Have a significant history of alcohol abuse or drug/solvent abuse

  5. Be unwilling to comply with any study assessments or procedures.

  6. Be a woman who is pregnant, nursing or planning a pregnancy.

  7. Be a woman of childbearing potential not using a highly effective method of birth control.

  8. Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.

    For the study eye:

  9. Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.

  10. Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),

  11. Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).

  12. Have severe blepharitis and/or severe meibomian gland disease in the study eye.

  13. Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.

  14. Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.

  15. Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.

  16. Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.

  17. Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.

  18. Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.

  19. Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.

  20. Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.

    For the fellow eye

  21. Have Stage 2 or 3 NK or perforation.

    For any eye:

  22. Have a history of ocular cancer.

  23. Have had prior treatment with Oxervate™

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Dose 1 - 0.5 µg/day

Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

다른 이름들:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

실험적: Dose 2 - 2.5 µg/day

Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

다른 이름들:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

실험적: Dose 3 - 5 µg/day

Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

다른 이름들:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

위약 비교기: Vehicle

Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID

Eye drop solution with no active substance in single dose unit.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Corneal Healing
기간: At week 8

The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre.

At week 8

2차 결과 측정

결과 측정
측정값 설명
기간
Visual Acuity
기간: At week 8

Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively).

At week 8

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 10월 13일

기본 완료 (실제)

2024년 4월 29일

연구 완료 (실제)

2024년 4월 29일

연구 등록 날짜

최초 제출

2020년 2월 17일

QC 기준을 충족하는 최초 제출

2020년 2월 17일

처음 게시됨 (실제)

2020년 2월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 14일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • REC0559-B-001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .